[Interleukin-2: molecular, physiological and pathophysiological bases and possible significance for clinical practice]
- PMID: 3303316
[Interleukin-2: molecular, physiological and pathophysiological bases and possible significance for clinical practice]
Abstract
Interleukin-2, a lymphokine produced by T lymphocytes in response to antigenic or mitogenic stimulation, is necessary for the proliferation and differentiation of various cell populations including activated T lymphocytes, natural killer cells (NK), lymphokine-activated killer cells (LAK), B lymphocytes and macrophages. In addition, IL2 induces or increases the production of important cytokines and thus plays a central role in regulation of the immune response. A number of studies have demonstrated that in patients with primary and secondary immunodeficiency disease, including patients with human immunodeficiency virus infections, decreased immune response was associated with impaired production of, or abnormal reaction to, IL2. Furthermore, IL2 has been assessed, alone or in combination with IL2-activated killer cells ("adoptive immunotherapy"), for its anticancer potential in several animal models and in patients with various forms of advanced cancer. A brief synopsis of biochemical and biological properties of IL2 is presented. The potential pathophysiological role of IL2 in a variety of immunodeficiency states and its possible therapeutic use in cancer therapy are discussed.
Similar articles
-
Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals.Nat Immun. 1996-1997;15(5):213-26. Nat Immun. 1996. PMID: 9390270
-
Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.Cancer Res. 1993 Dec 1;53(23):5654-62. Cancer Res. 1993. PMID: 8242620
-
Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.J Biol Response Mod. 1984 Oct;3(5):501-11. J Biol Response Mod. 1984. PMID: 6389777 Clinical Trial.
-
[Interleukin-2 and cancer treatment].Gan To Kagaku Ryoho. 1986 Jan;13(1):1-10. Gan To Kagaku Ryoho. 1986. PMID: 3510586 Review. Japanese.
-
Human natural killer cells: a comprehensive review.Int J Oncol. 2005 Jul;27(1):5-47. Int J Oncol. 2005. PMID: 15942642 Review.
Cited by
-
Placental ischemia-stimulated T-helper 17 cells induce preeclampsia-associated cytolytic natural killer cells during pregnancy.Am J Physiol Regul Integr Comp Physiol. 2018 Aug 1;315(2):R336-R343. doi: 10.1152/ajpregu.00061.2018. Epub 2018 May 2. Am J Physiol Regul Integr Comp Physiol. 2018. PMID: 29718698 Free PMC article.
-
Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.Int J Cancer. 2014 Sep 1;135(5):1132-41. doi: 10.1002/ijc.28745. Epub 2014 Feb 7. Int J Cancer. 2014. PMID: 24474467 Free PMC article.